Evaluation of dialysis centres: values and criteria of the stakeholders.
Delivery of health care
Health care quality assessment
Renal dialysis
Social values
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
14 Apr 2020
14 Apr 2020
Historique:
received:
01
10
2019
accepted:
09
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Evaluation of renal replacement therapy with haemodialysis is essential for its improvement. Remarkably, outcomes vary across centres. In addition, the methods used have important epistemological limitations, such as ignoring significant features (e.g., quality of life) or no relevance given to the patient's perspective in the indicator's selection. The present study aimed to determine the opinions and preferences of stakeholders (patients, clinicians, and managers) and establish their relative importance, considering the complexity of their interactions, to facilitate a comprehensive evaluation of haemodialysis centres. Successive working groups (WGs) were established using a multicriteria methodology. WG1 created a draft of criteria and sub-criteria, WG2 agreed, using a qualitative structured analysis with pre-established criteria, and WG3 was composed of three face-to-face subgroups (WG3-A, WG3-B, and WG3-C) that weighted them using two methodologies: weighted sum (WS) and analytic hierarchy process (AHP). Subsequently, they determined a preference for the WS or AHP results. Finally, via the Internet, WG4 weighted the criteria and sub-criteria by the method preferred by WG3, and WG5 analysed the results. WG1 and WG2 identified and agreed on the following evaluation criteria: evidence-based variables (EBVs), annual morbidity, annual mortality, patient-reported outcome measures (PROMs), and patient-reported experience measures (PREMs). The EBVs consisted of five sub-criteria: type of vascular access, dialysis dose, haemoglobin concentration, ratio of catheter bacteraemia, and bone mineral disease. The patients rated the PROMs with greater weight than the other stakeholders in both face-to-face WG3 (WS and AHP) and WG4 via the Internet. The type of vascular access was the most valued sub-criterion. A performance matrix of each criterion and sub-criterion is presented as a reference for assessing the results based on the preferences of the stakeholders. The use of a multicriteria methodology allows the relative importance of the indicators to be determined, reflecting the values of the different stakeholders. In a performance matrix, the inclusion of values and intangible aspects in the evaluation could help in making clinical and organizational decisions.
Sections du résumé
BACKGROUND
BACKGROUND
Evaluation of renal replacement therapy with haemodialysis is essential for its improvement. Remarkably, outcomes vary across centres. In addition, the methods used have important epistemological limitations, such as ignoring significant features (e.g., quality of life) or no relevance given to the patient's perspective in the indicator's selection. The present study aimed to determine the opinions and preferences of stakeholders (patients, clinicians, and managers) and establish their relative importance, considering the complexity of their interactions, to facilitate a comprehensive evaluation of haemodialysis centres.
METHODS
METHODS
Successive working groups (WGs) were established using a multicriteria methodology. WG1 created a draft of criteria and sub-criteria, WG2 agreed, using a qualitative structured analysis with pre-established criteria, and WG3 was composed of three face-to-face subgroups (WG3-A, WG3-B, and WG3-C) that weighted them using two methodologies: weighted sum (WS) and analytic hierarchy process (AHP). Subsequently, they determined a preference for the WS or AHP results. Finally, via the Internet, WG4 weighted the criteria and sub-criteria by the method preferred by WG3, and WG5 analysed the results.
RESULTS
RESULTS
WG1 and WG2 identified and agreed on the following evaluation criteria: evidence-based variables (EBVs), annual morbidity, annual mortality, patient-reported outcome measures (PROMs), and patient-reported experience measures (PREMs). The EBVs consisted of five sub-criteria: type of vascular access, dialysis dose, haemoglobin concentration, ratio of catheter bacteraemia, and bone mineral disease. The patients rated the PROMs with greater weight than the other stakeholders in both face-to-face WG3 (WS and AHP) and WG4 via the Internet. The type of vascular access was the most valued sub-criterion. A performance matrix of each criterion and sub-criterion is presented as a reference for assessing the results based on the preferences of the stakeholders.
CONCLUSIONS
CONCLUSIONS
The use of a multicriteria methodology allows the relative importance of the indicators to be determined, reflecting the values of the different stakeholders. In a performance matrix, the inclusion of values and intangible aspects in the evaluation could help in making clinical and organizational decisions.
Identifiants
pubmed: 32290836
doi: 10.1186/s12913-020-05085-w
pii: 10.1186/s12913-020-05085-w
pmc: PMC7155312
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297Subventions
Organisme : Miguel Servet Foundation of Navarra (Spain)
ID : 2015
Organisme : "la Caixa" Foundation
ID : 2015
Références
Am J Kidney Dis. 2019 Mar;73(3):372-384
pubmed: 30579710
BMJ. 2018 May 17;361:k2014
pubmed: 29773537
Value Health. 2016 Jan;19(1):1-13
pubmed: 26797229
J Am Soc Nephrol. 2015 Nov;26(11):2621-33
pubmed: 26209712
Kidney Int. 2018 Dec;94(6):1053-1068
pubmed: 30360959
Lancet. 2007 Feb 24;369(9562):698-700
pubmed: 17321316
Value Health. 2012 Dec;15(8):1172-81
pubmed: 23244821
Patient Prefer Adherence. 2015 Jun 26;9:847-55
pubmed: 26170634
Soc Sci Med. 2007 Apr;64(8):1754-65
pubmed: 17258367
Health Expect. 2015 Oct;18(5):661-75
pubmed: 24325553
Implement Sci. 2010 May 26;5:39
pubmed: 20504357
Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1703-12
pubmed: 27197911
Int J Technol Assess Health Care. 2013 Oct;29(4):353-9
pubmed: 23845404
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):190-199
pubmed: 28062678
Patient Prefer Adherence. 2016 Dec 13;10:2491-2500
pubmed: 28008235
BMJ. 2013 Jan 28;346:f167
pubmed: 23358487
Nephrol Dial Transplant. 2015 Oct;30(10):1605-14
pubmed: 25982327
Health Qual Life Outcomes. 2017 May 2;15(1):52
pubmed: 28460638
Nephrol Dial Transplant. 2017 Oct 1;32(10):1737-1749
pubmed: 28057873
J Eval Clin Pract. 2017 Jun;23(3):477-485
pubmed: 26662940
Patient. 2010;3(4):229-248
pubmed: 21394218
Nephrol Dial Transplant. 2011 Nov;26(11):3709-14
pubmed: 21427072
Nephrol Dial Transplant. 2009 Dec;24(12):3557-66
pubmed: 19820003
Value Health. 2016 Mar-Apr;19(2):125-37
pubmed: 27021745